$CLPT News

ClearPoint Neuro to Announce Third Quarter 2026 Results October 28, 2026

ClearPoint Neuro Shares Fall 24% Following uniQure AMT-130 Trial Update

ClearPoint Neuro (CLPT) Stock Sees Fair Value Cut As Analysts Factor In Heavier Investment

ClearPoint Neuro (CLPT) Q2 2026 Earnings Call Transcript

ClearPoint Neuro: Regulatory Momentum Strengthens The Long-Term Investment Case

ClearPoint Neuro, Inc. Q2 2026 Earnings Call Summary

ClearPoint Neuro, Inc. (CLPT) Q2 2026 Earnings Call Transcript

ClearPoint Neuro (CLPT) Reports Q2 Earnings: What Key Metrics Have to Say

ClearPoint Neuro Q2 Earnings Call Highlights

ClearPoint Neuro Reports Second Quarter 2026 Results

ClearPoint Neuro Lowers FY2026 Sales Guidance from $52.000M-$56.000M to $48.000M-$52.000M vs $53.133M Est

ClearPoint Neuro Q2 EPS $(0.38) Misses $(0.29) Estimate, Sales $10.880M Miss $12.733M Estimate

ClearPoint Neuro Congratulates Partner Aspen Neuroscience on FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Sasineprocel

ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026

Why I've (Reluctantly) Sold My ClearPoint Neuro Position

B. Riley Securities Maintains Buy on ClearPoint Neuro, Raises Price Target to $30

ClearPoint Neuro: AMT-130's FDA Reversal Revives The Bull Case

ClearPoint Neuro Shares Jump as FDA Progress for UniQure Therapy Highlights Platform Value

ClearPoint Neuro Enters into 10-year Focused Ultrasound Development Partnership with Sungkyunkwan University, South Korea, Further Expanding Our Drug Delivery Ecosystem and Global Footprint

ClearPoint Neuro Collaborates With SONOCARELAB To Tap Focused Ultrasound Market